BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34568719)

  • 1. Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction.
    Whitman ED; Koshenkov VP; Gastman BR; Lewis D; Hsueh EC; Pak H; Trezona TP; Davidson RS; McPhee M; Guenther JM; Toomey P; Smith FO; Beitsch PD; Lewis JM; Ward A; Young SE; Shah PK; Quick AP; Martin BJ; Zolochevska O; Covington KR; Monzon FA; Goldberg MS; Cook RW; Fleming MD; Hyams DM; Vetto JT
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34568719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma.
    Marchetti MA; Dusza SW; Bartlett EK
    JAMA Dermatol; 2022 Jun; 158(6):680-683. PubMed ID: 35475908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Integrated i31-GEP Test Outperforms the MSKCC Nomogram at Predicting SLN Status in Melanoma Patients.
    Tassavor M; Martin BJ; Glazer AM
    Anticancer Res; 2023 Oct; 43(10):4511-4516. PubMed ID: 37772588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
    Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
    Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test.
    Jarell A; Gastman BR; Dillon LD; Hsueh EC; Podlipnik S; Covington KR; Cook RW; Bailey CN; Quick AP; Martin BJ; Kurley SJ; Goldberg MS; Puig S
    J Am Acad Dermatol; 2022 Dec; 87(6):1312-1320. PubMed ID: 35810840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma.
    Aiken TJ; Stahl CC; Schwartz PB; Barrett J; Acher AW; Lemaster D; Leverson G; Weber S; Neuman H; Abbott DE
    J Surg Oncol; 2021 Jan; 123(1):104-109. PubMed ID: 32939750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should Sentinel Lymph Node Biopsy Be Performed for All T1b Melanomas in the New 8
    Egger ME; Stevenson M; Bhutiani N; Jordan AC; Scoggins CR; Philips P; Martin RC; McMasters KM
    J Am Coll Surg; 2019 Apr; 228(4):466-472. PubMed ID: 30660817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of the clinicopathologic and gene expression profile (CP-GEP) in patients with melanoma eligible for sentinel lymph node biopsy: A multicenter prospective Dutch study.
    Stassen RC; Mulder EEAP; Mooyaart AL; Francken AB; van der Hage J; Aarts MJB; van der Veldt AAM; Verhoef C; Grünhagen DJ
    Eur J Surg Oncol; 2023 Dec; 49(12):107249. PubMed ID: 37907016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study.
    Yousaf A; Tjien-Fooh FJ; Rentroia-Pacheco B; Quattrocchi E; Kobic A; Tempel D; Kolodney M; Meves A
    Int J Dermatol; 2021 Jul; 60(7):851-856. PubMed ID: 33914348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma.
    Hieken TJ; Grotz TE; Comfere NI; Inselman JW; Habermann EB
    Melanoma Res; 2015 Apr; 25(2):157-63. PubMed ID: 25647736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Mitotic Rate Predicts Sentinel Lymph Node Involvement in Thin Melanomas.
    Skochdopole AJ; Kutlu OC; Engelhardt KE; Lancaster WP; Abbott AM; Camp ER
    J Surg Res; 2020 Dec; 256():198-205. PubMed ID: 32711176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
    Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
    Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas.
    Patuzzo R; Maurichi A; Camerini T; Gallino G; Ruggeri R; Baffa G; Mattavelli I; Tinti MC; Crippa F; Moglia D; Tolomio E; Maccauro M; Santinami M
    J Surg Res; 2014 Apr; 187(2):518-24. PubMed ID: 24252855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.
    Vetto JT; Hsueh EC; Gastman BR; Dillon LD; Monzon FA; Cook RW; Keller J; Huang X; Fleming A; Hewgley P; Gerami P; Leachman S; Wayne JD; Berger AC; Fleming MD
    Future Oncol; 2019 Apr; 15(11):1207-1217. PubMed ID: 30691297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel lymph node biopsy in melanoma: beyond histologic factors.
    Carr MJ; Monzon FA; Zager JS
    Clin Exp Metastasis; 2022 Feb; 39(1):29-38. PubMed ID: 34100196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study.
    Yamamoto M; Sickle-Santanello B; Beard T; Essner R; Martin B; Bailey CN; Guenther JM
    Curr Med Res Opin; 2023 Mar; 39(3):417-423. PubMed ID: 36617959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
    Han D; Zager JS; Shyr Y; Chen H; Berry LD; Iyengar S; Djulbegovic M; Weber JL; Marzban SS; Sondak VK; Messina JL; Vetto JT; White RL; Pockaj B; Mozzillo N; Charney KJ; Avisar E; Krouse R; Kashani-Sabet M; Leong SP
    J Clin Oncol; 2013 Dec; 31(35):4387-93. PubMed ID: 24190111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
    Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
    Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
    Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
    Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a scoring system to predict non-sentinel lymph node metastasis in melanoma.
    Cadili A; McKinnon G; Wright F; Hanna W; Macintosh E; Abhari Z; Dabbs K
    J Surg Oncol; 2010 Mar; 101(3):191-4. PubMed ID: 20039281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.